Abbott has secured approval from the US Food and Drug Administration (FDA) for its new optical coherence tomography (OCT) imaging platform powered by Ultreon Software.

The advanced imaging software integrates OCT with artificial intelligence (AI) to offer physicians with an improved and comprehensive view of coronary blood flow and blockages, thereby helping in efficient decision-making and treatment.

By combining Abbott’s new Dragonfly OpStar imaging catheter and PressureWire X guidewire, Ultreon Software helps physicians to gain access to a range of tools to evaluate coronary blood flow and blockages and enhance treatment planning for patients.

Abbott’s vascular business global medical affairs divisional vice president and chief medical officer Dr Nick West said: “As cardiologists continue to adopt OCT and move away from traditional imaging methods such as angiography, emerging technologies are pivotal to determine the best course of patient care.

“AI enables Ultreon Software to automatically detect calcium and vessel diameters allowing doctors to put stents exactly where they are needed.”

The US regulator’s clearance for the OCT imaging platform follows the recent CE mark approval in Europe, allowing interventional cardiologists to use the AI-powered technology.

In addition, the company secured approval for Ultreon Software in Japan.

Abbott stated its recent data demonstrated that physicians have changed their treatment strategy in treating 88% of coronary artery blockages, when OCT is paired with the company’s MLD MAX, a new workflow that allows to guide and optimise stenting decisions.

In May this year, Abbott launched a new trial to improve treatment options for patients suffering from both atrial fibrillation (AFib) and heart failure.